{
    "organizations": [],
    "uuid": "df6c652b30000581de4020bc3b5eecb8293e7952",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alimera-sciences-receives-acceptan/brief-alimera-sciences-receives-acceptance-of-filing-to-obtain-approval-for-iluvien-idUSFWN1OZ0MO",
    "ord_in_thread": 0,
    "title": "BRIEF-Alimera Sciences Receives Acceptance Of Filing To Obtain Approval For Iluvien",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 4, 2018 / 12:34 PM / Updated 9 minutes ago BRIEF-Alimera Sciences Receives Acceptance Of Filing To Obtain Approval For Iluvien Reuters Staff 1 Min Read \nJan 4 (Reuters) - Alimera Sciences Inc: \n* ALIMERA SCIENCES RECEIVES ACCEPTANCE OF FILING TO OBTAIN APPROVAL FOR ILUVIENÂ® NON-INFECTIOUS POSTERIOR UVEITIS INDICATION IN EUROPE Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T14:33:00.000+02:00",
    "crawled": "2018-01-04T14:47:18.036+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "science",
        "receives",
        "acceptance",
        "filing",
        "obtain",
        "approval",
        "iluvien",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "alimera",
        "science",
        "inc",
        "alimera",
        "science",
        "receives",
        "acceptance",
        "filing",
        "obtain",
        "approval",
        "posterior",
        "uveitis",
        "indication",
        "europe",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}